

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

NCT07329036

Status	RECRUITING
Phase	Not Applicable
Sponsor	Institute for Clinical and Experimental Medicine
Enrollment	25 participants

Key Eligibility Criteria

Inclusion (6)

- Adult patient, age ≥18 years
- Expressed consent to the inclusion
- Patient hospitalized on ICU with ALF or ACLF diagnosis
- Recently meeting the inclusion to liver transplantation
- Present on a waiting list to liver transplant
- ... and 1 more (see full listing online)

Exclusion (5)

- Disagreement with the study
- Infaust prognosis with expected survival less than 24 hours
- Physiologically/biologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3.
- Advanced oncological disease (expected life expectancy below 6 months)
- Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according

Locations (1 total)

Institute for Clinical and Experimental Medicine (IKEM), Prague, Czechia

<https://clinicaltrials.gov/study/NCT07329036>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).